# LEVANTIS-0093A (GAGome test in high-risk adults)

Source: https://onco.cc/trials/lev93a/  
OnCo record `lev93a` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A UK study testing Elypta's plasma sugar-molecule test for many cancers in heavy smokers taking part in lung screening.

## Summary

LEVANTIS-0093A (NCT05295017) is an observational study sponsored by Elypta. It validates the plasma free GAGome multi-cancer test using samples and data from the Yorkshire Lung Screening Trial and Yorkshire Kidney Screening Trial.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 19 September 2024), with 1,235 participants enrolled, a start on 14 March 2022 and primary completion expected in October 2025.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: LEV93A
- Registry id: NCT05295017
- Phase: observational
- Setting: Adults aged 55 to 80 with a significant smoking history in the Yorkshire Lung Screening Trial biomarker substudy
- Sponsor: Elypta
- Enrolled: 1235

## Sources

- ClinicalTrials.gov NCT05295017: https://clinicaltrials.gov/study/NCT05295017

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Elypta GAGome multi-cancer test](https://onco.cc/drugs/gagome-mced-test/)
- companies: [Elypta](https://onco.cc/companies/elypta/)

---
JSON: https://onco.cc/api/v1/entities/lev93a.json